Semax, explained.
Research, safety questions, and treatment context.
The form
More than one catalog form
The routine
A clinic wellness schedule cannot be inferred from stroke-rehabilitation protocols.
The evidence
Human research in a different clinical setting
Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- Backed by FDA advisers, awaiting final rule
FDA advisers voted 8 to 5 on July 24, 2026 to allow compounding, for migraine and specific neurological conditions.
- At Goodmorrow
- Waitlist open
What it is
Semax is a synthetic peptide based on a fragment of ACTH, a pituitary hormone. It's taken as a nasal spray.
What the evidence shows
Semax has more clinical use behind it than most peptides on this list because of its Russian approval, but most of those studies haven't been repeated elsewhere. The FDA reviewed it for migraine, cerebral ischemia and trigeminal neuralgia, not for everyday focus.
How Goodmorrow handles it
If it becomes lawful, we'll consider it case by case. We won't sell it as a productivity hack.
Follow updates about Semax
Join the update list. This does not reserve a treatment or mean that future availability is assured.
Questions people ask
Is Semax a nootropic?
It's marketed as one. The studies behind it are about stroke and nerve conditions, not focus in healthy people.
Sources
- Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceFDA advisory committee nominates six peptides for pharmacies to compound National Community Pharmacists Association, July 31, 2026
Good days ahead.
Join the opening list for appointment updates.